EVO News and Press, Evotec SE From 05/17/22

Germany-based Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and Canada's Sernova (OTCQB:SEOVF) are collaborating to develop a therapy for diabetes. The companies plan to develop an implantable iPSC-based beta cell replacement therapy to treat insulin-dependent diabetes, including type 1 and 2. Under...

The ADRs of Evotec SE (NASDAQ:EVO) (OTCPK:EVOTF) have surged in the pre-market Tuesday after the German biotech announced an eight-year extension for its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation. Per the terms, the parties will make full use of Evotec’...

HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, ori...

8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS $ 2...

HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the res...

Evotec SE (EVO) Q4 2021 Earnings Conference Call April 12, 2022 08:00 ET Company Participants Werner Lanthaler - Chairman and Chief Executive Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Enno Spillner - Chief Financial Officer Conference Call Part...

STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE...

THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICALS HAMBURG, GERMANY / ACCESSWIRE / Apri...

HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022. The Company is going to hold a conference call to discuss the results as well as to...

Evotec SE (NASDAQ:EVO) announced on Monday that it received a €3 million worth of milestone payment from German conglomerate Bayer AG (OTCPK:BAYZF) (OTCPK:BAYRY) for clinical work related to a potential treatment for diabetic neuropathic pain ("DNP"). The payment was triggered by the d...